The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Drugs in development for toxoplasmosis: advances, challenges, and current status
Open accessAbstract
Abstract: Toxoplasma gondii causes fatal and debilitating brain and eye diseases. Medicines that are currently used to treat toxoplasmosis commonly have toxic side effects and require prolonged courses that range from weeks to more than a year. The need for long treatment durations and the risk of relapsing disease are in part due to the lack of efficacy against T . gondii tissue cysts. The challenges for developing a more effective treatment for toxoplasmosis include decreasing toxicity, achieving therapeutic concentrations in the brain and eye, shortening duration, eliminating tissue cysts from the host, safety in pregnancy, and creating a formulation that is inexpensive and practical for use in resource-poor areas of the world. Over the last decade, significant progress has been made in identifying and developing new compounds for the treatment of toxoplasmosis. Unlike clinically used medicines that were repurposed for toxoplasmosis, these compounds have been optimized for efficacy against toxoplasmosis during preclinical development. Medicines with enhanced efficacy as well as features that address the unique aspects of toxoplasmosis have the potential to greatly improve toxoplasmosis therapy. This review discusses the facets of toxoplasmosis that are pertinent to drug design and the advances, challenges, and current status of preclinical drug research for toxoplasmosis. Keywords: Toxoplasma gondii , therapeutics, preclinical medicine, experimental medicine, mechanism of action, Apicomplexa
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxoplasma gondii: from animals to humans
Tenter, A. M., Heckeroth, A. R., & Weiss, L. M. (2000) · International Journal for Parasitology · doi:10.1016/s0020-7519(00)00124-7 · Cited by 3,702
Epidemiology of and Diagnostic Strategies for Toxoplasmosis
Robert-Gangneux, F., & Dardé, M.-L. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05013-11 · Cited by 1,815
Bisphosphonates: Mechanism of action and role in clinical practice
Drake, M. T., Clarke, B. L., & Khosla, S. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.9.1032 · Cited by 1,644
DNA gyrase, topoisomerase IV, and the 4-quinolones.
Drlica, K., & Zhao, X. (1997) · Microbiology and molecular biology reviews : MMBR · doi:10.1128/.61.3.377-392.1997 · Cited by 1,494
Spiroindolones, a Potent Compound Class for the Treatment of Malaria
Rottmann, M., McNamara, C., Yeung, B. K. S., Lee, M. C. S., Zou, B., Russell, B., Seitz, P., Plouffe, D. M., Dharia, N. V., Tan, J., et al. (2010) · Science · doi:10.1126/science.1193225 · Cited by 1,206
Pappas, G., Roussos, N., & Falagas, M. E. (2009) · International Journal for Parasitology · doi:10.1016/j.ijpara.2009.04.003 · Cited by 1,161
Morpholino Antisense Oligomers: Design, Preparation, and Properties
SUMMERTON, J., & WELLER, D. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.187 · Cited by 1,116
FATTY ACID SYNTHESIS AND ITS REGULATION
Wakil, S. J., Stoops, J. K., & Joshi, V. C. (1983) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.52.070183.002541 · Cited by 1,026
A Genome-wide CRISPR Screen in Toxoplasma Identifies Essential Apicomplexan Genes
Sidik, S. M., Huet, D., Ganesan, S. M., Huynh, M.-H., Wang, T., Nasamu, A. S., Thiru, P., Saeij, J. P. J., Carruthers, V. B., Niles, J. C., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.019 · Cited by 804
A Plastid of Probable Green Algal Origin in Apicomplexan Parasites
Köhler, S., Delwiche, C. F., Denny, P. W., Tilney, L. G., Webster, P., Wilson, R. J. M., Palmer, J. D., & Roos, D. S. (1997) · Science · doi:10.1126/science.275.5305.1485 · Cited by 760
Cited by
Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice
Dunay, I. R., Gajurel, K., Dhakal, R., Liesenfeld, O., & Montoya, J. G. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00057-17 · Cited by 553
Control of human toxoplasmosis
Smith, N. C., Goulart, C., Hayward, J. A., Kupz, A., Miller, C. M., & van Dooren, G. G. (2021) · International Journal for Parasitology · doi:10.1016/j.ijpara.2020.11.001 · Cited by 286
Tissue tropism in parasitic diseases
Silva Pereira, S., Trindade, S., De Niz, M., & Figueiredo, L. M. (2019) · Open Biology · doi:10.1098/rsob.190036 · Cited by 85
Toxoplasma gondii vaccine candidates: a concise review
Mamaghani, A. J., Fathollahi, A., Arab-Mazar, Z., kohansal, K., Fathollahi, M., Spotin, A., Bashiri, H., & Bozorgomid, A. (2023) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-022-02998-9 · Cited by 51
Promising drug targets and compounds with anti-Toxoplasma gondii activity
Silva, M. D., Teixeira, C., Gomes, P., & Borges, M. (2021) · Microorganisms · doi:10.3390/microorganisms9091960 · Cited by 44
Metadata
- Authors
- Alday, H., & Doggett, J.
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2017-01
- Volume
- Volume11
- Pages
- 273-293
- ISSN
- 1177-8881 (ISSN-L)
- OpenAlex
- W2580625752
- Cited by
- 321
- References
- 104
- FWCI
- 17.23
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drugs in development for toxoplasmosis: advances, challenges, and current status. https://app.cochat.ai/papers/10.2147/dddt.s60973
- The paper
- Alday, H., & Doggett, J. (2017). Drugs in development for toxoplasmosis: advances, challenges, and current status. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s60973
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.